XCUR
Price
$1.29
Change
-$0.12 (-8.51%)
Updated
Aug 28 closing price
Capitalization
8.44M
Intraday BUY SELL Signals
XFOR
Price
$4.04
Change
-$0.19 (-4.49%)
Updated
Aug 28 closing price
Capitalization
400.55M
59 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

XCUR vs XFOR

XCUR vs XFOR Comparison Chart in %
View a ticker or compare two or three
VS
XCUR vs. XFOR commentary
Aug 31, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is XCUR is a Buy and XFOR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 31, 2026
Stock price -- (XCUR: $1.29 vs. XFOR: $4.04)
Brand notoriety: XCUR and XFOR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: XCUR: 20% vs. XFOR: 35%
Market capitalization -- XCUR: $8.44M vs. XFOR: $400.55M
XCUR [@Biotechnology] is valued at $8.44M. XFOR’s [@Biotechnology] market capitalization is $400.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $137.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

XCUR’s FA Score shows that 0 FA rating(s) are green whileXFOR’s FA Score has 0 green FA rating(s).

  • XCUR’s FA Score: 0 green, 5 red.
  • XFOR’s FA Score: 0 green, 5 red.
According to our system of comparison, XFOR is a better buy in the long-term than XCUR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

XCUR’s TA Score shows that 6 TA indicator(s) are bullish while XFOR’s TA Score has 3 bullish TA indicator(s).

  • XCUR’s TA Score: 6 bullish, 2 bearish.
  • XFOR’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, XCUR is a better buy in the short-term than XFOR.

Price Growth

XCUR (@Biotechnology) experienced а +12.17% price change this week, while XFOR (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.46%. For the same industry, the average monthly price growth was +11.42%, and the average quarterly price growth was +2520.78%.

Reported Earning Dates

XFOR is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (+3.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XFOR($401M) has a higher market cap than XCUR($8.44M). XFOR has higher P/E ratio than XCUR: XFOR (2.83) vs XCUR (0.19). XFOR YTD gains are higher at: 1.000 vs. XCUR (-76.199). XCUR has higher annual earnings (EBITDA): -3.7M vs. XFOR (-89.88M). XFOR has more cash in the bank: 234M vs. XCUR (2.6M). XCUR has less debt than XFOR: XCUR (22K) vs XFOR (77.3M). XFOR has higher revenues than XCUR: XFOR (9.01M) vs XCUR (0).
XCURXFORXCUR / XFOR
Capitalization8.44M401M2%
EBITDA-3.7M-89.88M4%
Gain YTD-76.1991.000-7,620%
P/E Ratio0.192.837%
Revenue09.01M-
Total Cash2.6M234M1%
Total Debt22K77.3M0%
FUNDAMENTALS RATINGS
XCUR vs XFOR: Fundamental Ratings
XCUR
XFOR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
9352
P/E GROWTH RATING
1..100
10060
SEASONALITY SCORE
1..100
5034

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XFOR's Valuation (48) in the Biotechnology industry is in the same range as XCUR (49) in the null industry. This means that XFOR’s stock grew similarly to XCUR’s over the last 12 months.

XFOR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as XCUR (100) in the null industry. This means that XFOR’s stock grew similarly to XCUR’s over the last 12 months.

XFOR's SMR Rating (99) in the Biotechnology industry is in the same range as XCUR (99) in the null industry. This means that XFOR’s stock grew similarly to XCUR’s over the last 12 months.

XFOR's Price Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for XCUR (93) in the null industry. This means that XFOR’s stock grew somewhat faster than XCUR’s over the last 12 months.

XFOR's P/E Growth Rating (60) in the Biotechnology industry is somewhat better than the same rating for XCUR (100) in the null industry. This means that XFOR’s stock grew somewhat faster than XCUR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
XCURXFOR
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
86%
Momentum
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
84%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
XCUR
Daily Signal:
Gain/Loss:
XFOR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
POST85.353.86
+4.74%
Post Holdings
AIDX0.630.02
+3.21%
20/20 Biolabs Inc
NMR10.300.18
+1.78%
Nomura Holdings
TXO14.50-0.14
-0.96%
TXO Partners LP
CHPT5.57-0.26
-4.46%
ChargePoint Holdings

XCUR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XCUR has been loosely correlated with XFOR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if XCUR jumps, then XFOR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XCUR
1D Price
Change %
XCUR100%
-8.51%
XFOR - XCUR
34%
Loosely correlated
-4.49%
HRTX - XCUR
26%
Poorly correlated
-1.66%
NNVC - XCUR
25%
Poorly correlated
-3.12%
PLX - XCUR
25%
Poorly correlated
-2.68%
KRYS - XCUR
24%
Poorly correlated
-1.68%
More